Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
1.
Clin Microbiol Infect ; 10(12): 1067-74, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15606633

ABSTRACT

Therapy with interferon and ribavirin for hepatitis C virus (HCV) infection induces a decrease in several haematological population counts. It is unclear whether haematological toxicity is more severe in patients co-infected with HCV and human immunodeficiency virus (HIV). This study analysed the evolution of haematological population counts during and after interferon and ribavirin therapy for chronic HCV infection. Eleven patients co-infected with HIV and HCV and treated with pegylated interferon plus ribavirin, and ten treated with standard interferon plus ribavirin, were analysed. With reference to baseline values, neutrophil counts decreased by an average of 45% (range 18-67%), total lymphocytes by 50% (16-63%), CD4 lymphocytes by 54% (16-61%), haemoglobin by 9% (5-16%) and platelets by 31% (16-45%). The nadir of the decrease was reached in the first weeks of therapy and was maintained while patients were receiving treatment. The reduction in all series was higher with pegylated interferon. Patients recovered their baseline counts after finishing the treatment. No cases of haemorrhage or outstanding infection were detected during follow-up.


Subject(s)
Antiviral Agents/adverse effects , HIV Infections/blood , Hematologic Diseases/chemically induced , Hepatitis C, Chronic/drug therapy , Interferon-alpha/adverse effects , Polyethylene Glycols/adverse effects , Ribavirin/adverse effects , AIDS-Related Opportunistic Infections , Adult , Antiviral Agents/therapeutic use , Blood Cell Count , Drug Therapy, Combination , Female , HIV Infections/complications , HIV-1 , Hemorrhage/chemically induced , Hepatitis C, Chronic/complications , Humans , Interferon alpha-2 , Interferon-alpha/therapeutic use , Male , Polyethylene Glycols/therapeutic use , Prospective Studies , Recombinant Proteins , Ribavirin/therapeutic use
2.
Enferm Infecc Microbiol Clin ; 21(10): 543-51, 2003 Dec.
Article in Spanish | MEDLINE | ID: mdl-14642252

ABSTRACT

INTRODUCTION: To assess the long-term effectiveness, safety and response-related factors in a cohort of HIV-infected persons receiving antiretroviral therapy containing nelfinavir. Design and setting. Prospective, non-randomized multicenter study. METHOD: A total of 792 patients were included: 254 (32.1%) treatment-naive patients and 538 (67.9%) patients previously treated with protease inhibitors who were switched to a nelfinavir-containing regimen due to virological failure or intolerance. Factors related to virological response and to treatment failure were assessed by standard survival techniques and Cox proportional risk models. RESULTS: Nelfinavir was well tolerated; treatment had to be interrupted in only 57 patients (7.1%) because of toxicity. During a median follow-up of 12 months, 31 patients (3.9%) experienced a new AIDS-defining event or death, and 463 (58.4%) showed immunological response. Overall, 52% patients achieved plasma HIV-1 RNA levels below 500 copies/mL (57% of naive and 49% of previously treated patients), but a high rate of virological rebound (24% and 49%, respectively) was observed. Low baseline viral load and few prior treatments were factors related to virological response. Naive treatment status and a high increase in CD4 cell count were predictive of longer viral response. CONCLUSIONS: Highly active antiretroviral therapy with a nelfinavir-containing regimen was associated with favorable virological response in nearly half of previously treated patients, and most experienced clinical and immunological benefits. Nevertheless, the limited duration of virological response indicates the need for new alternative drugs.


Subject(s)
Antiretroviral Therapy, Highly Active , HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , Nelfinavir/therapeutic use , Adult , Aged , Cohort Studies , Female , Follow-Up Studies , HIV Infections/immunology , HIV Infections/virology , Humans , Male , Middle Aged , Prospective Studies
3.
Article in Es | IBECS | ID: ibc-26457

ABSTRACT

INTRODUCCIÓN. Evaluar la eficacia, tolerancia y factores asociados a la respuesta a largo plazo en una cohorte de pacientes infectados por el virus de la inmunodeficiencia humana (VIH) con un tratamiento que incluya nelfinavir. DISEÑO. Estudio prospectivo y multicéntrico, no aleatorizado. MÉTODO. Se incluyeron un total de 792 pacientes: 254 (32,1 por ciento) sin ningún tratamiento previo y 538 (67,9 por ciento) previamente tratados con inhibidores de la proteasa (IP) que cambiaron a un régimen con nelfinavir. El análisis se realizó mediante el método de curvas actuariales de Kaplan-Meier y modelos de riesgo proporcional de Cox. RESULTADOS. Nelfinavir fue bien tolerado y tan sólo 57 pacientes (7,1 por ciento) interrumpieron el tratamiento debido a efectos secundarios. Tras un año de seguimiento medio, 31 pacientes (3,9 por ciento) tuvieron un nuevo episodio definitorio de sida o muerte y se observó respuesta inmunológica en 463 (58,4 por ciento). Globalmente, el 52 por ciento de los pacientes alcanzó una carga viral indetectable (57 por ciento de vírgenes y 49 por ciento de pretratados), pero un alto porcentaje de ellos (24 y 49 por ciento, respectivamente) experimentó un rebrote tras una favorable respuesta inicial. Los factores relacionados con la respuesta virológica fueron una baja carga viral al inicio y un menor número de tratamientos previos. Los pacientes sin tratamiento previo y con una respuesta inmunológica mayor tuvieron una respuesta viral más duradera. CONCLUSIONES. El tratamiento antirretroviral con nelfinavir consigue una respuesta viral favorable en casi la mitad de los pacientes pretratados y la mayoría experimentan un beneficio clínico e inmunológico. Sin embargo, la limitada durabilidad de la respuesta virológica pone de manifiesto la necesidad de nuevos fármacos alternativos (AU)


Subject(s)
Middle Aged , Adult , Aged , Male , Female , Humans , Antiretroviral Therapy, Highly Active , HIV Infections , Cohort Studies , HIV Protease Inhibitors , Prospective Studies , Nelfinavir , Follow-Up Studies
5.
Rev Clin Esp ; 199(12): 790-5, 1999 Dec.
Article in Spanish | MEDLINE | ID: mdl-10687411

ABSTRACT

In order to analyze the nutritional status of HIV infected patients and the involvement of the tumour necrosis factor-alpha (TNF-alpha) and its soluble receptors (sTNFRI and sTNFRII) in such an status, forty HIV infected patients, with no associated systemic opportunist infections, were prospectively followed for eight months. From each patient the following were obtained: clinical history, dietetic survey, anthropometric measurements, CD4+ T lymphocyte/mm3 count, HIV load, and serum concentration of TNF and sTNFRI and sTNFRII. Patients showed a nutritional disorder which involved mainly the fat compartment (mean tricipital skin fold 9.8 +/- 4.2 mm, that is, 65.7 +/- 27.4% of the ideal fold), associated with a hypocaloric intake (mean daily intake 1,659.5 +/- 543.0 kcal), with normal proportions of the different organic principles. Serum concentrations of TNF (87.9 +/- 79.2 vs 8.7 +/- 6.1 pg/ml, p = 0.048) and its receptors, sTNFRI (6.1 +/- 2.6 vs 1.0 +/- 0.8 pg/ml, p < 0.001) and sTNFRII (41.9 +/- 18.6 vs 6.3 +/- 3.6 pg/ml, p < 0.001) were significantly higher than those detected in a sample of ten healthy controls. No correlation was found between nutritional alterations and concentrations of TNF or its receptors, viral load, and counts of CD4+ T lymphocytes/mm3. Seventeen patients completed the follow-up period. During this period, no significant modifications in the analyzed parameters were observed: tricipital skin fold, arm circumference, serum concentrations of albumin or transferrin, concentrations of tumoral necrosis factor or its receptor and caloric intake. The conclusion is that, despite the detected nutritional alterations in the nutritional status and those in the TNF/receptor system, our data no support and interrelationship between them.


Subject(s)
Acquired Immunodeficiency Syndrome/blood , Nutritional Status , Receptors, Tumor Necrosis Factor/blood , Tumor Necrosis Factor-alpha/analysis , Adult , Female , Humans , Male , Prospective Studies
6.
Enferm Infecc Microbiol Clin ; 16(7): 322-7, 1998.
Article in Spanish | MEDLINE | ID: mdl-9808882

ABSTRACT

OBJECTIVE: Analysis of the spectrum of diseases attributed to Pseudomonas aeruginosa in patients with coinfection with the immunodeficiency virus (HIV). METHODS: Retrospective study of 35 cases of coinfection with P. aeruginosa-HIV, attended from 1985 until 1995. Analysis of putative factors implicated in mortality secondary to P. aeruginosa infection. RESULTS: The spectrum of infection due to P. aeruginosa was: ORL infection (4 cases), infection of upper respiratory tract (4 cases), pneumonia (21 cases), infected bronchiectasias (one case), endocarditis (2 cases) and primary bacteremia (3 cases). Most of these infections were community-acquired ones (30 cases [85.7%]). Degree of immunodepression was variable, with 12 cases (34.3%) affecting to patients with more than 200 CD4+lymphocytes x 10(-9)/l. Radiological pattern of pneumonias consisted in alveolar consolidation (18 cases [85.7%]), necrotizing pneumonia (2 cases [9.5%]) and interstitial pattern (one case [4.8%]). More than a 80% of isolates of P. aeruginosa was sensible to ceftazidime, ciprofloxacin, aminoglycosides, ureidopenicillins and imipenem. Recidives of the P. aeruginosa infection were detected in 7 cases (20%): 4 cases of ORL infection (100%) and 3 cases of lower respiratory tract infection (13.6%). Overall mortality was a 20% (7 cases), being directly attributed to P. aeruginosa infection in every one of the cases, all of them pneumonias. Secondary bacteremia was associated to a higher mortality (odds ratio [OR] 18.67; p = 0.0207). CONCLUSIONS: P. aeruginosa affect to the HIV-infected patients, independently of their immunodepression degree, affecting to different localizations. This bacteria continues to be sensible to conventional anti-Pseudmonas treatment. Pneumonia with secondary bacteremia is associated to a higher mortality.


Subject(s)
AIDS-Related Opportunistic Infections , Pseudomonas Infections , AIDS-Related Opportunistic Infections/diagnosis , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/epidemiology , Adult , Female , Humans , Male , Pseudomonas Infections/diagnosis , Pseudomonas Infections/drug therapy , Pseudomonas Infections/epidemiology , Retrospective Studies , Spain/epidemiology
8.
Eur J Clin Microbiol Infect Dis ; 16(11): 807-15, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9447902

ABSTRACT

In order to analyze the etiology, cytological and biochemical characteristics, and outcome of pleural disease in patients infected with HIV, the medical records of 86 HIV-positive patients with pleural effusion were reviewed. Controls were 106 HIV-negative patients with parapneumonic or tuberculous effusion. Most HIV-positive patients were intravenous drug abusers (95.3%). Pleural effusions in HIV-positive patients were caused by infections in 76 (89.4%) cases. Parapneumonic effusion was diagnosed in 59 patients and tuberculous pleuritis in 15 patients. Staphylococcus aureus was the most frequently isolated bacteria. Parameters for differentiating complicated cases of parapneumonic exudate from uncomplicated cases, such as pleural fluid pH < 7.20 (sensitivity 80% vs. 84.3%), pleural fluid glucose < 35 mg/dl (sensitivity 45% vs. 56.25%) pleural fluid LDH > 1600 UI/l (sensitivity 85% vs. 62.50%), showed similar sensitivity in HIV-positive and HIV-negative patients. Monocytes in pleural fluid were significantly decreased in tuberculous pleuritis in HIV-positive patients (506 +/- 425 vs. 1014 +/- 1196 monocytes/ml, p < 0.05). No significant differences were detected in the outcome of HIV-positive and HIV-negative patients with pleural disease. It can be concluded that the pleural effusion was of predominantly infectious etiology in HIV-positive patients from populations with a high prevalence of intravenous drug abuse. Neither the biochemical parameters in pleural fluid nor the outcome differed significantly between HIV-positive and HIV-negative patients.


Subject(s)
HIV Infections/complications , Pleural Effusion/etiology , Adult , Aged , Bacteria/isolation & purification , CD4 Lymphocyte Count , Female , Humans , Hydrogen-Ion Concentration , L-Lactate Dehydrogenase/analysis , Male , Middle Aged
9.
Eur J Clin Microbiol Infect Dis ; 13(7): 559-64, 1994 Jul.
Article in English | MEDLINE | ID: mdl-7805683

ABSTRACT

In a prospective study, a two-week course of antibiotics (cloxacillin 2 g/4 h plus amikacin 7.5 mg/kg/12 h) was evaluated in the therapy of right-sided infective endocarditis in intravenous drug users (IVDU). All IVDU admitted to hospital during the study period who fulfilled the strict criteria for diagnosis of infective endocarditis were analysed. A subgroup of patients with right-sided endocarditis caused by Staphylococcus aureus who had a good prognosis were selected as being eligible for the two-week course of treatment. In a total of 139 episodes of infective endocarditis in IVDU, 72 (51.8%) cases were eligible for the two-week treatment. Of this group, 67 were cured, 4 needed prolongation of treatment to cure the infection and 1 died in hospital of respiratory distress syndrome on day 10 of treatment. In patients not eligible for the two-week treatment, the mortality was higher (24.2% versus 0.7%; p = 0.00015). Drug toxicity in the treated group was low. It can be concluded that administration of cloxacillin and amikacin parenterally for 14 consecutive days was successful in the therapy of right-sided endocarditis in IVDU.


Subject(s)
Drug Therapy, Combination/therapeutic use , Endocarditis, Bacterial/drug therapy , Staphylococcal Infections/drug therapy , Substance Abuse, Intravenous/complications , Adult , Amikacin/therapeutic use , Cloxacillin/therapeutic use , Drug Therapy, Combination/administration & dosage , Female , Humans , Infusions, Intravenous , Male , Prospective Studies
11.
Med Clin (Barc) ; 98(14): 521-6, 1992 Apr 11.
Article in Spanish | MEDLINE | ID: mdl-1602849

ABSTRACT

BACKGROUND: Given the progressive increase in infectious endocarditis (IE) in intravenous drug addicts (IVDA) in the province of Cadiz the present study was designed with the aim of studying the epidemiologic and clinical characteristics of this disease in our environment. METHODS: One hundred fifty episodes of IE occurring in 133 IVDA admitted to 6 hospitals in the province of Cadiz were studied in an open, multicentric study with a protocol of gathering of common data. Well known diagnostic criteria were used for this process and a univariant technique was employed in the analysis of prognostic factors. RESULTS: Fifty-three percent of the episodes occurred in the county of Campo de Gibraltar and 32% in the area of the Bay of Cadiz. The increase of the disease has been progressive since 1984 and marked over the last two years. All the patients presented fever, abnormal chest radiography in 90% and the process was produced by Staphylococcus aureus in 88%. Echography was abnormal in 85% of the episodes and vegetation was identified in 75%. The IE was located as right in 90%, mixed in 5% and left in 5%. Surgical treatment was required in 4 patients. Mortality was of 9%. Mixed or left location (p = 0.00003) and the development of the respiratory distress syndrome of the adult (p = 0.00001) were significantly associated with greater mortality. CONCLUSIONS: Infectious endocarditis in intravenous drug addicts maintains a well defined pattern of clinical expressivity and presents identifiable factors of prognostic influence. The increase in its prevalence in the province of Cadiz is probably due to a parallel increase in the addiction to intravenous heroin in this area.


Subject(s)
Endocarditis, Bacterial/epidemiology , Heroin Dependence/epidemiology , Substance Abuse, Intravenous/epidemiology , Adolescent , Adult , Endocarditis, Bacterial/complications , Endocarditis, Bacterial/etiology , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/therapy , Female , Heroin Dependence/complications , Humans , Male , Prognosis , Retrospective Studies , Spain/epidemiology , Substance Abuse, Intravenous/complications
SELECTION OF CITATIONS
SEARCH DETAIL
...